Highlights on the management of aggressive lymphomas

Dr. Willem Daneels, hematologist at UZ Ghent, provides valuable insights on the management of aggressive lymphomas. He presents the outcomes of a non-inferiority trial comparing observation versus radiotherapy in patients with primary mediastinal b-cell lymphoma who had a complete metabolic response after standard immunochemotherapy. The final results of the hovon/sakk trial evaluating r-codox-m/r-ivac versus da-epoch-r in patients with newly diagnosed high-risk burkitt lymphoma are also discussed.

Dr. Daneels evaluates the potential of a biomarker-driven treatment strategy in high-risk large b-cell lymphoma patients. He concludes his highlights with the primary overall survival analysis of the ZUMA‑7 study with axicabtagene ciloleucel in relapsed/refractory large b-cell lymphoma patients.

With the educational support of: